Mundipharma to present bendamustine data at ASH meeting Pharmaceutical Business Review Two oral and three poster presentations will present summary on indolent NHL (iNHL) and MCL, comparing treatment with bendamustine-rituximab (B-R) to the standard first-line treatment, CHOP-R/CVP-R as well as another study, demonstrating enhanced ... |
